XENE Relative Valuation
XENE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XENE is overvalued; if below, it's undervalued.
Historical Valuation
Xenon Pharmaceuticals Inc (XENE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -12.08. The fair price of Xenon Pharmaceuticals Inc (XENE) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 32.17 USD , Xenon Pharmaceuticals Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：32.17
Fair
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
3.44
P/B
Median3y
3.50
Median5y
3.33
-8.27
FCF Yield
Median3y
-5.15
Median5y
-5.32
Competitors Valuation Multiple
The average P/S ratio for XENE's competitors is 37.66, providing a benchmark for relative valuation. Xenon Pharmaceuticals Inc Corp (XENE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Xenon Pharmaceuticals Inc (XENE) currently overvalued or undervalued?
What is Xenon Pharmaceuticals Inc (XENE) fair value?
How does XENE's valuation metrics compare to the industry average?
What is the current P/B ratio for Xenon Pharmaceuticals Inc (XENE) as of Jul 18 2025?
What is the current FCF Yield for Xenon Pharmaceuticals Inc (XENE) as of Jul 18 2025?
What is the current Forward P/E ratio for Xenon Pharmaceuticals Inc (XENE) as of Jul 18 2025?